Providing Answers, Support and Hope in Georgia
Investigational New Drug, Eque-cel, Receives FDA Approval for Lupus Nephritis and Non-Renal Systemic Lupus Erythematosus Treatment
The new drug application for the investigational therapy, Equecabtagene Autoleucel or Eque-cel, for treatment of lupus nephritis (LN) and non-renalsystemic lupus erythematosus (SLE) was approved by the U.S. Food and Drug Administration.
Eque-cell is a fully human B-cell maturation antigen (anti-BCMA) CAR T cell therapy injection designed to help reset the immune system. The therapy targets and destroys BCMA-expressing cells, eliminates activated B-cells and plasma cells in people with SLE, calms autoimmune inflammation and eases disease symptoms.
The therapy has been proven to be safe and effective for treatment of relapsed/refractoryautoantibody-mediated neurological diseases. Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.